



## Original Article



## Diagnostic Accuracy of Fasting Blood Sugar and Oral Glucose Challenge Test for Gestational Diabetes Mellitus

Kinza Ayesha<sup>1</sup>, Aisha Ajmal<sup>1</sup>, Arooj Akram<sup>1</sup>, Joveria Sadaf<sup>1</sup>, Fareeha Usman<sup>1</sup> and Sana Hafeez<sup>1</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, Shahida Islam Teaching Hospital, Lodhran, Pakistan

## ARTICLE INFO

**Keywords:**

Fasting Blood Glucose, Gestational Diabetes, Gold Standard, Glucose Challenge Test

**How to Cite:**

Ayesha, K., Ajmal, A., Akram, A., Sadaf, J., Usman, F., & Hafeez, S. (2025). Diagnostic Accuracy of Fasting Blood Sugar and Oral Glucose Challenge Test for Gestational Diabetes Mellitus: Fasting Blood Sugar and Oral Glucose Challenge Test for GDM. *Pakistan Journal of Health Sciences*, 6(4), 142-147. <https://doi.org/10.54393/pjhs.v6i4.2914>

**\*Corresponding Author:**

Arooj Akram  
Department of Obstetrics and Gynecology, Shahida Islam Teaching Hospital, Lodhran, Pakistan  
[akramarooj2222@gmail.com](mailto:akramarooj2222@gmail.com)

Received date: 2<sup>nd</sup> March, 2025

Revised date: 25<sup>th</sup> April, 2025

Acceptance date: 27<sup>th</sup> April, 2025

Published date: 30<sup>th</sup> April, 2025

## ABSTRACT

Despite multiple studies on gestational diabetes mellitus (GDM) screening, evidence on the concurrent validity and practical use of fasting blood glucose (FBS) and glucose challenge test (GCT) remains limited. **Objectives:** To compare the diagnostic accuracy of FBS, and oral GCT in detecting GDM, taking oral glucose tolerance test (OGTT) as the gold standard. **Methods:** This cross-sectional study was conducted at the Department of Obstetrics and Gynecology, Shahida Islam Teaching Hospital, Lodhran, Pakistan, from March to December 2023. A total of 160 pregnant women aged 20-40 years (gestation > 20 weeks) were included. Diagnostic performance of FBS and GCT was assessed using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. IBM-SPSS Statistics, version 26.0, was used for data analysis. McNemar's test was applied to these how FBS, or GCT, agreed with GTT in diagnosing GDM, taking  $p < 0.05$  as significant. **Results:** The mean age and gestational age were  $29.54 \pm 5.35$  years and  $27.81 \pm 2.48$  weeks, respectively. The sensitivity of FBS in the diagnosis of GDM was 78.3%, and that of GCT was 84.2% ( $p = 0.700$ ). The specificity of FBS and GCT was 86.8% and 96.9%, respectively. The PPV of FBS was 81.8%, and that of GCT was 85.7%. The NPV of FBS and GCT were 84.0% and 91.8%, respectively ( $p = 0.994$ ). Accuracy of FBS was 83.1%, and GCT was 89.4%. **Conclusions:** It was concluded that the diagnostic accuracy of FBS and GCT in diagnosing GDM is high, with GCT demonstrating superior effectiveness. OGTT remains the definitive gold standard for confirming GDM.

## INTRODUCTION

Gestational diabetes mellitus (GDM) is a condition occurring in pregnancy associated with significant complications, and its prevalence is rising, particularly among Asian women [1]. The prevalence of GDM varies between 4.4% and 57.9% in Pakistan [2]. Research has shown a strong association of GDM with many adverse pregnancy outcomes like macrosomia, polyhydramnios, shoulder dystocia, preeclampsia, higher cesarean delivery rates, and long-term effects on both mothers and infants [3]. Females with GDM are estimated to have a raised risk of developing type 2 diabetes mellitus (T2DM) in the following years of life. Management strategies for GDM, including exercise, dietary changes, blood glucose monitoring, and insulin therapy, have evolved over the years and resulted in

improved management of associated short-term and long-term complications [4]. No screening test is universally accepted despite the rising prevalence and impact of GDM globally. Not only do the diagnostic tests, but also the criteria for diagnosis, vary widely. According to ACOG and ADA, universal screening should be done with oral glucose tolerance test (OGTT) between 24-28th week of pregnancy. Fasting blood sugar (FBS) is often used for GDM screening due to its affordability, accessibility, simplicity, and reliability [5, 6]. The debate still goes on about the diagnostic accuracy (DA) of the glucose challenge test (GCT) and FBS levels [7-9]. Asians, particularly Pakistani women, have a high prevalence of diabetes and genetic susceptibility to metabolic syndromes with an elevated risk

of developing GDM and its associated complications. This highlights the need for a cost-effective, universal screening and diagnostic approach. GCT seems less time-consuming, although no consensus guidelines or endorsements exist in this regard. FBS is easier to obtain, but it needs the patient to come fasting. The high accuracy of FBS could alleviate the strain on laboratories and conserve resources, as conducting a 2-hour, 75g OGTT can be challenging in large populations and resource-limited areas. This study was conducted to collect data from the local population to help identify more accurate, less time and cost-effective tests so that this research may help in formulating national protocols and guidelines for the diagnosis of GDM.

Gestational diabetes mellitus (GDM) is a rapidly increasing pregnancy complication associated with significant maternal and fetal risks, particularly in high-risk populations like Pakistan. Although OGTT is the gold standard for diagnosis, it is resource-intensive and less feasible in low-resource settings, while simpler tests like FBS and GCT show variable diagnostic performance. However, there is limited local evidence directly comparing the diagnostic accuracy and practical applicability of FBS and GCT against OGTT in Pakistani pregnant women. This study aims to compare the diagnostic accuracy of FBS and GCT in identifying GDM, using the OGTT as the gold standard, in pregnant women attending a tertiary care hospital. Despite numerous international and national studies on GDM screening, there remains limited evidence evaluating the concurrent validity and practical applicability of FBS and GCT in low-resource, peripheral tertiary care settings within Pakistan. This study seeks to provide context-specific data to inform more feasible and cost-effective screening strategies for early GDM detection in such environments.

## METHODS

It was a cross-sectional validation study conducted in the Department of Obstetrics and Gynecology, Shahida Islam Teaching Hospital, Lodhran, from 1<sup>st</sup> March 2023 to 30<sup>th</sup> December 2023. A sample size of 160 cases was calculated, taking the frequency of GDM as 11.8%, with a 95% confidence level, and a 5% margin of error using the Open EPI online sample size calculator [10]. The sample was selected by non-probability, consecutive sampling. Women, 20-40 years of age, presenting after the 20<sup>th</sup> week of gestation, who came to the outpatient department for their antenatal check-ups, were included. All patients with a history of chronic hypertension, multiple gestation, obesity, history of diabetes, chronic liver disease, and chronic kidney disease were excluded. After obtaining approval from the ethical committee of the institution (letter number: SIMC/ET.C/10013/23), women fulfilling eligibility criteria were enrolled from the outpatient

department following informed and written consent. Data about age, gestational age (as per LMP), body mass index (BMI), residence, monthly income, and family history of DM were collected. Blood samples were sent to the institutional laboratory to measure FBG on two consecutive days. On day 1, the patients also underwent a 50g non-fasting GCT. One week later, during their next visit, the patients received a 75 g OGTT. The results of the gold standard were then compared with those from the FBG and GCT. FBG  $\geq 92$  mg/dL was considered positive for GDM. The 50g GCT, performed without fasting, was considered positive if  $\geq 200$  mg/dl. The OGTT confirmed GDM if glucose levels exceeded fasting  $\geq 92$  mg/dL, 1-hour  $\geq 180$  mg/dL, or 2-hour  $\geq 153$  mg/dL. Data analysis was done by IBM-SPSS Statistics 26.0. Mean and standard deviation were calculated for quantitative variables. Frequencies and percentages were determined for qualitative variables. The diagnostic evaluation analysis calculated sensitivity, specificity, PPV, NPV, and DA. McNemar's test was applied to these to determine how FBS, or GCT, agreed with GTT in diagnosing GDM, taking  $p < 0.050$  as significant.

## RESULTS

In a total of 160 women, the mean age was  $29.54 \pm 5.35$  years, while 87 (54.38%) were between 20-30 years. The mean gestational age was  $27.81 \pm 2.48$  weeks, while the mean BMI was  $30.43 \pm 2.66$  kg/m<sup>2</sup>. Distribution of patients according to parity, place of living, family history of DM, and monthly family income is shown in Table 1.

**Table 1:** Characteristics of Women with Gestational Diabetes Mellitus (n=160)

Variables	Frequency (%)	
Age in Years	20-30	87 (54.4%)
	31-40	73 (45.6%)
BMI (Kg/M <sup>2</sup> )	$\leq 27$	29 (18.1%)
	$>27$	131 (81.9%)
Parity	1-2	73 (45.6%)
	3-5	87 (54.4%)
Place of Living	Rural	65 (40.6%)
	Urban	95 (59.4%)
Family History of Diabetes	Yes	56 (35.0%)
	No	104 (65.0%)
Monthly Income (PKR)	<25000	33 (20.6%)
	25000-50000	76 (47.5%)
	>50000	51 (31.9%)

In 66 blood FPG positive women, 54 had GDM, and 12 had no GDM on GTT. Among 94 FPG negative patients, 15 had GDM on GTT, whereas 79 had no GDM on GTT ( $p=0.700$ ). Overall sensitivity, specificity, PPV, NPV, and DA of FPG in detecting GDM, taking GTT as gold standard, were 78.3%, 86.8%, 81.8%, 84.0% and 83.1%, respectively. In 63 GCT-positive women, 54 had GDM, and 9 had no GDM on GTT. Among 97 GCT negative women, 8 had GDM on GTT, whereas 89 had no GDM on GTT ( $p=0.994$ ). Overall

sensitivity, specificity, PPV, NPV, and DA of GCT for detecting GDM were 84.2%, 96.9%, 85.7%, 91.8%, and 89.4%, respectively and shown in table 2.

**Table 2:** Diagnostic Validity of Fasting Blood Sugar and Oral Glucose Challenge Test Concerning Oral Glucose Tolerance Test in Diagnosing Gestational Diabetes Mellitus

Variables	Positive GTT	Negative GTT	p-value	Sensitivity	Specificity	PPV	NPV	DA
Positive FBS	54 (TP)	12 (FP)	0.700	78.3%	86.8%	81.8%	84.0%	83.1%
Negative FBS	15 (FN)	79 (TN)						
Positive GCT	54 (TP)	09 (FP)	0.994	87.1%	90.8%	85.7%	91.8%	89.4%
Negative GCT	08 (FN)	89 (TN)						

Among women aged 20–30 years, FBS demonstrated a sensitivity of 80.4%, specificity of 85.9%, and diagnostic accuracy of 83.4%. In women with BMI >27 kg/m<sup>2</sup>, sensitivity and specificity were 77.6% and 87.5%, respectively. Diagnostic accuracy ranged from 82.5% to 83.5% across BMI strata. Similar trends were observed by parity, with accuracy for FBS being 84.1% in women with 1–2 children and 83.7% in those with 3–5 children. The details about the stratified diagnostic utility evaluation of FBS in diagnosing gestational diabetes mellitus concerning the oral glucose tolerance test are shown in Table 3.

**Table 3:** Stratified Diagnostic Utility Evaluation of Fasting Blood Sugar in Diagnosing Gestational Diabetes Mellitus Concerning Oral Glucose Tolerance Test

Variables		Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	DA (%)
Age in Years	20-30	80.4%	85.9%	78.0%	86.1%	83.4%
	31-40	76.2%	88.4%	85.7%	83.4%	83.2%
BMI (kg/m <sup>2</sup> )	≤27	82.8%	84.4%	76.4%	88.6%	82.5%
	>27	77.6%	87.5%	83.6%	83.7%	83.5%
Parity	1-2	79.1%	88.1%	80.2%	85.4%	84.1%
	3-5	78.0%	86.8%	82.0%	84.3%	83.7%
Place of Living	Rural	76.5%	85.4%	79.9%	83.4%	82.2%
	Urban	79.4%	87.6%	83.4%	84.7%	84.9%
Family History of Diabetes	Yes	77.5%	86.5%	81.6%	84.3%	83.5%
	No	78.5%	87.2%	82.3%	85.7%	83.4%
Monthly Income (PR)	<25000	75.4%	84.6%	77.7%	81.7%	81.5%
	25000–50000	79.9%	86.7%	81.2%	85.2%	83.6%
	>50000	81.0%	88.9%	85.0%	86.6%	84.5%

In women aged 20–30 and 31–40 years, GCT yielded diagnostic accuracies of 89.2% and 89.8%, respectively. For BMI >27 kg/m<sup>2</sup>, sensitivity was 86.5% and specificity 97.5%, with 89.6% DA. Urban women had slightly better diagnostic performance (accuracy 89.5%) compared with rural women (88.5%). GCT also showed robust accuracy in women with (89.5%) and without (89.5%) a family history of diabetes. The details about the stratified diagnostic utility evaluation of FBS in diagnosing gestational diabetes mellitus for the oral glucose tolerance test are shown in Table 4.

**Table 4:** Stratified Diagnostic Utility Evaluation of Glucose Challenge Test in Diagnosing Gestational Diabetes Mellitus Concerning Oral Glucose Tolerance Test

Characteristics		Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	DA (%)
Age in Years	20-30	85.5%	95.1%	83.0%	92.7%	89.2%
	31-40	89.9%	98.3%	88.1%	91.2%	89.8%
BMI (kg/m <sup>2</sup> )	≤ 27	88.2%	94.4%	84.7%	93.9%	87.2%
	>27	86.5%	97.5%	87.5%	91.5%	89.6%
Parity	1-2	86.7%	97.2%	85.1%	92.6%	89.5%
	3-5	88.6%	96.9%	87.2%	92.4%	89.5%
Place of Living	Rural	84.4%	95.4%	84.7%	91.2%	88.5%
	Urban	88.5%	97.4%	87.2%	92.7%	89.5%
Family History of Diabetes	Yes	85.5%	96.5%	86.9%	91.2%	89.5%
	No	88.1%	97.2%	87.4%	92.1%	89.5%
Monthly Income (PR)	<25000	82.0%	94.6%	82.3%	90.8%	87.5%
	25000–50000	88.9%	96.7%	85.4%	91.0%	89.7%

	>50000	90.4%	98.2%	89.5%	93.4%	90.6%
--	--------	-------	-------	-------	-------	-------

## DISCUSSION

Having a convenient method for screening and early diagnosis of GDM is crucial. A significant drawback of the gold standard for detecting GDM (OGTT at 24 weeks) is that it is typically assessed late in the second trimester, which can increase the risk of developing various health problems [11]. This study showed that FBG had a sensitivity of 78.3%, specificity of 86.8%, PPV of 81.8%, NPV of 84.0%, and DA of 83.1%. Oral GCT exhibited sensitivity of 84.2%, specificity of 96.9%, PPV of 85.7%, NPV of 91.8%, and DA of 89.4%. The findings of this study align closely with another study, which reported FBG sensitivity as 97.0%, specificity 78.2%, PPV 17.8%, and NPV 99.81% for screening GDM [7]. Another local study found FBG sensitivity to be 96.77%, specificity at 98.4%, PPV 98.6%, NPV 96.3%, and DA at 97.5%, also taking OGTT as the gold standard, and these findings, along with the present research, exhibit the efficiency of FBG in screening for GDM [8]. A meta-analysis indicated pooled sensitivity and specificity for GCT at 79.0% and 74.0%, respectively, while FBG had pooled sensitivity and specificity of 81.0% and 70.0%, further reinforcing the utility of FBG in GDM screening as was exhibited in the present study [9]. Some experts advocate for screening for previously undiagnosed diabetes during pregnancy, especially in populations at higher risk [12]. The primary advantage of FBG testing is its ability to diagnose overt diabetes, especially when FPG levels exceed 125 mg/dl. While the IADPSG in 2010 recommended GDM to be diagnosed with FBS between 92–125 mg/dl at any point during pregnancy, this recommendation has faced criticism due to insufficient supporting evidence [13]. A study done by Souha AA concluded that GCT > 140 mg/dl is an effective threshold due to high NPV, and also the specificity to rule out GDM. This study also stated that lowering the threshold to 135 mg/dl increases the sensitivity, but the specificity decreases [14]. Salini et al., showed that the 75g GCT demonstrated significantly greater DA compared to other methods. The authors also advocated that this GCT could replace all existing screening approaches and may serve as an alternative to the two-step 100g OGTT [15]. In this study, FBG ≥ 92 mg/dL was considered positive for GDM, and this threshold has been a popular endorsement by other researchers like Chukwunyerre et al., who revealed that a FBG threshold of 92 mg/dl to exhibit excellent diagnostic performance, achieving a sensitivity of 90.0% and a specificity of 97.1%, along with an area under the curve as 0.920 [16]. In comparison, the random plasma glucose (RPG) threshold of 140 mg/dl demonstrated a much lower sensitivity of 13.8%, although it maintained a specificity of 97.1%, resulting in an

AUC of 0.845. These findings support the consideration of FBG as a viable standalone alternative for GDM screening, and the present study reinforces these findings [17]. Beunen et al., showed FBG < 78 mg/dl was identified as the optimal cut-off for minimizing missed cases of GDM, resulting in 44 missed cases (19.0%) with a NPV of 97.3%. This approach also helped to avoid 52.2% of OGTTs. Women with this FBG level exhibited a more favourable metabolic profile and, among those with normal glucose tolerance, showed reduced fetal growth [18]. Hasan et al., concluded that, FBG cut-off value of 81 mg/dl can serve as an effective initial screening test for GDM, helping to minimize the need for OGTTs [19]. Overall sensitivity, specificity, PPV, NPV, and DA of FPG in detecting GDM, taking GTT as gold standard, were 78.3%, 86.8%, 81.8%, 84.0% and 83.1%, respectively, showing the effectiveness of FPG screening for GDM. A study from India comparing GCT versus OGTT indicated that the GCT may overlook a significant number of pregnancies while screening for GDM, and recommended using the OGTT as the more established as well as effective diagnostic approach for GDM [20]. A study from South Africa concluded that universal screening and diagnosis of GDM are commonly recommended to enhance treatment and improve pregnancy outcomes; this approach could often be unfeasible in many resource-constrained settings [21]. This study is limited by its single-center design, relatively small sample size, and non-probability sampling, which may affect generalizability. Additionally, variability in patient compliance and potential selection bias may influence diagnostic outcomes. Future large-scale, multicenter studies with randomized sampling are recommended to validate these findings across diverse populations. It is also suggested that combined screening strategies and cost-effectiveness analyses be explored to develop standardized, resource-appropriate guidelines for early GDM detection in low- and middle-income settings.

## CONCLUSIONS

It was concluded that both FBG and GCT are highly accurate in identifying GDM, with GCT demonstrating superior effectiveness. However, OGTT remains the definitive gold standard for confirming the diagnosis of GDM. Utilizing GCT as a primary screening tool may aid in early detection, allowing timely referral for OGTT and thereby helping to prevent complications associated with undiagnosed GDM.

## Authors' Contribution

Conceptualization: JS

Methodology: KA, AA1, AA2, FU, SH

Formal analysis: FU

Writing and Drafting: JS

Review and Editing: JS, KA, AA1, AA2, FU, SH

All authors approved the final manuscript and take responsibility for the integrity of the work

## Conflicts of Interest

All the authors declare no conflict of interest.

## Source of Funding

The author received no financial support for the research, authorship and/or publication of this article.

## REFERENCES

- [1] Li LJ, Huang L, Tobias DK, Zhang C. Gestational Diabetes Mellitus Among Asians—A Systematic Review from a Population Health Perspective. *Frontiers in Endocrinology*. 2022 Jun;13:840331. doi:10.3389/fendo.2022.840331.
- [2] Adnan M and Aasim M. Prevalence of Gestational Diabetes Mellitus in Pakistan: A Systematic Review and Meta-Analysis. *BioMed Central Pregnancy and Childbirth*. 2024 Feb;24(1):108. doi:10.1186/s12884-024-06290-9.
- [3] Pénager C, Bardet P, Timsit J, Lepercq J. Determinants of the Persistency of Macrosomia and Shoulder Dystocia Despite Treatment of Gestational Diabetes Mellitus. *Heliyon*. 2020 Apr;6(4). doi:10.1016/j.heliyon.2020.e03756.
- [4] Benhalima K. Recent Advances in Gestational Diabetes Mellitus. *Journal of Clinical Medicine*. 2021 May;10(10):2202. doi:10.3390/jcm10102202.
- [5] Shaarbaq Eidgahi E, Nasiri M, Kariman N, Safavi Ardebili N, Salehi M, Kazemi M et al. Diagnostic Accuracy of First and Early Second Trimester Multiple Biomarkers for Prediction of Gestational Diabetes Mellitus: A Multivariate Longitudinal Approach. *BioMed Central Pregnancy and Childbirth*. 2022 Jan;22(1):13. doi:10.1186/s12884-021-04348-6.
- [6] Li M, Lan JR, Liang JL, Xiong XL. Diagnostic Accuracy of Fasting Plasma Glucose as a Screening Test for Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis. *European Review for Medical and Pharmacological Sciences*. 2020 Nov;24(21).
- [7] Thakur A, Agrawal S, Chakole S, Wandile B. A Critical Review of Diagnostic Strategies and Maternal Offspring Complications in Gestational Diabetes Mellitus. *Cureus*. 2023 Dec;15(12). doi:10.7759/cureus.51016.
- [8] Tomimoto M, Tanimura K, Masuko N, Uchida A, Imafuku H, Deguchi M et al. Problems in Screening for Gestational Diabetes Mellitus by Measurement of Casual Blood Glucose Levels at 24–28 Gestational Weeks. *Journal of Diabetes Investigation*. 2024 Dec;15(12):1797–802. doi:10.1111/jdi.14310.
- [9] Sfameni SF, Wein P, Sfameni AM. Establishing Novel Diagnostic Criteria for the Glucose Tolerance Test for the Diagnosis of Gestational Diabetes and Gestational Hyperglycemia. *International Journal of Gynecology and Obstetrics*. 2024 Feb;164(2):758–62. doi:10.1002/ijgo.15074.
- [10] Riaz M, Nawaz A, Masood SN, Fawwad A, Basit A, Shera AS. Frequency of Gestational Diabetes Mellitus Using DIPSI Criteria, A Study from Pakistan. *Clinical Epidemiology and Global Health*. 2019 Jun;7(2):218–21. doi:10.1016/j.cegh.2018.06.003.
- [11] Amini M, Kazemnejad A, Zayeri F, Montazeri A, Rasekhi A, Amirian A et al. Diagnostic Accuracy of Maternal Serum Multiple Marker Screening for Early Detection of Gestational Diabetes Mellitus in the Absence of a Gold Standard Test. *BioMed Central Pregnancy and Childbirth*. 2020 Dec;20:1–9. doi:10.1186/s12884-020-03068-7.
- [12] Huhn EA, Rossi SW, Hoesli I, Göbl CS. Controversies in Screening and Diagnostic Criteria for Gestational Diabetes in Early and Late Pregnancy. *Frontiers in Endocrinology*. 2018 Nov;9:696. doi:10.3389/fendo.2018.00696.
- [13] ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. *Diabetes Care* 2023; 46 (Suppl. 1): S19–S40. *Diabetes Care*. 2023 May;46(5):1106–. doi:10.2337/dc23-er05.
- [14] Souha AA. Performance Characteristics of the 50-Gram Glucose Challenge Test Compared to the 75 Gram Oral Glucose Tolerance Test for Gestational Diabetes Screening at the Kenyatta National Hospital (Doctoral dissertation, University of Nairobi). 2019.
- [15] Salini KM, Kumari V, Sahay PB. Evaluation of 75 gm Glucose Challenge Test as One Step Screening /Diagnostic Test for Gestational Diabetes Mellitus. *Journal of Pharmaceutical Negative Results*. 2023;13(6):3915–3923.
- [16] Chukwunyere CF, Awonuga DO, Adesina OF, Udenze IC. Gestational Diabetes: Comparison of Random and Fasting Plasma Glucose as Modalities of Screening. *Diabetes*. 2020 Nov. doi:10.33590/emjdiabet/20-00119.
- [17] Zhao G, Murphy KE, Berger H, Shah BR, Halperin I, Barrett J et al. The Screening Performance of Glucose Challenge Test for Gestational Diabetes in Twin Pregnancies: A Systematic Review and Meta-Analysis. *The Journal of Maternal-Fetal and Neonatal Medicine*. 2022 Dec;35(25):7590–600. doi:10.1080/14767058.2021.1956896.
- [18] Beunen K, Neys A, Van Crombrugge P, Moyson C, Verhaeghe J, Vandeginste S et al. Fasting Plasma Glucose Level to Guide the Need for an OGTT to Screen for Gestational Diabetes Mellitus. *Acta Diabetologica*. 2022 Mar:1–4.

- [19] Hasan MR, Sultana N, Panthi S, Hasan M, Jahan S, Aktar Y et al. Fasting Plasma Glucose as a Primary Screening Test for the Diagnosis of Gestational Diabetes Mellitus. medRxiv.2024Aug:2024-08.doi:10.1101/2024.08.23.24312519.
- [20] Saxena RK, Ansari NF, Singh P. Effectiveness of Diabetes in Pregnancy Study Group India Diagnostic Criterion in Detecting Gestational Diabetes Mellitus: A Rural Bangalore Study. International Journal of Reproduction, Contraception, Obstetrics and Gynecology.2020Feb;9(2):602.doi:10.18203/2320-1770.ijrcog20200344.
- [21] Dias S, Pheiffer C, Rheeder P, Adam S. Screening and Diagnosis of Gestational Diabetes Mellitus in South Africa: What We Know So Far. South African Medical Journal.2019Jul;109(7):457-62.doi:10.7196/SAMJ.2019.v109i7.14064.